EndoArt s.r.o.
- Address
- Hladnovska 1255/23, 710 00 Slezska Ostrava, Czechia
EndoArt s.r.o. - Inflammatory Bowel Disease Research Center
EndoArt s.r.o. is a specialized clinical research facility dedicated to advancing therapeutic options for patients suffering from inflammatory bowel diseases (IBD). The center demonstrates particular expertise in conducting Phase 2 and Phase 3 clinical trials that evaluate both novel biologic agents and oral therapeutic formulations for complex gastrointestinal conditions.
- Advanced therapies for moderately to severely active Crohn's Disease, including long-term extension studies and novel oral agents
- Treatment strategies for moderate to severe ulcerative colitis with focus on clinical remission and endoscopic response
- Evaluation of mesalazine formulations for mild to moderate ulcerative colitis management
The research center's portfolio encompasses comprehensive assessment of endoscopic outcomes and clinical remission endpoints in IBD populations. With experience in both induction and maintenance therapy trials, EndoArt s.r.o. employs rigorous methodologies including double-blind, placebo-controlled designs and centralized endoscopic reading to ensure the highest quality of clinical data. Their commitment to long-term safety and efficacy evaluation positions them as a valuable contributor to the development of next-generation IBD therapeutics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in EndoArt s.r.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Oral Zasocitinib in Patients with Moderately to Severely Active Crohn's Disease: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study | Takeda Development Center Americas Inc. | Phase II | Recruiting | Sep 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 3 | Unknown | 2024-09-04 | 2025-08-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.